Chicago, IL – February 11, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include The Procter & Gamble Co. PG, Boston Scientific Corp. BSX, ConocoPhillips COP and Kewaunee Scientific Corp. KEQU.
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Co., Boston Scientific Corp. and ConocoPhillips, as well as a micro-cap stock, Kewaunee Scientific Corp. The Zacks microcap research is unique, as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market open and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
Procter & Gamble’s shares have outperformed the Zacks Consumer Products - Staples industry over the past six months (+1.9% vs. -1.8%). The company is gaining from a strategy that focuses on sustainability and adaptability, responding to the evolving demands of consumers.
Procter & Gamble has been focused on productivity and cost-saving plans to boost margins. This led to the bottom line beating the consensus mark for the tenth consecutive quarter in second-quarter fiscal 2025. PG reiterated its view for fiscal 2025. PG estimates organic sales to grow 3-5% for the fiscal year versus our estimate of a 3% growth.
However, PG has been witnessing headwinds related to the market issues in Greater China, geopolitical tensions, and financial impacts from currency volatility. PG’s fiscal 2025 EPS view includes an after-tax headwind of $200 million related to unfavorable commodity costs, and adverse currency.
(You can read the full research report on Procter & Gamble here >>>)
Shares of Boston Scientific have outperformed the Zacks Medical - Products industry over the past year (+62% vs. +16.3%). The company is seeing strength across target markets. Strong worldwide demand for its MedSurg and Cardiovascular lines, traction in the United States and outside for its the next generation WATCHMAN FLX and FLX Pro, as well as contribution from accretive acquisitions are important drivers.
The Pain and Brain franchisees are expected to gain solid traction in 2025 banking on strong execution of core growth strategies. The Electrophysiology arm continues to gain momentum on sustained adoption of FARAPULSE PFA. The 2025 guidance indicating strong organic growth over 2024 builds confidence in the stock.
On the flip side, mounting costs due to worldwide geopolitical issues are major concerns. FX headwinds are expected to impact the company’s top line in 2025.
ConocoPhillips’ have underperformed the Zacks Oil and Gas - Integrated - United States industry over the past year (-9% vs. -6.9). The company’s significant dependence on crude oil makes it vulnerable to market fluctuations. Furthermore, declining free cash flows and rising total costs due to inflationary pressures add to the concern.
Nevertheless, ConocoPhillips is set to leverage its extensive, untapped drilling locations in cost-effective and diverse upstream assets like Eagle Ford Shale, the Permian Basin, and Bakken Shale. The acquisition of Marathon Oil Corporation should expand its regional footprint in these key areas. ConocoPhillips is also strategically increasing its presence in the liquefied natural gas market to meet growing energy transition demands.
ConocoPhillips’ low debt exposure strengthens its ability to sustain dividend payments. ConocoPhillips reported better-than-expected fourth-quarter earnings primarily due to higher oil equivalent production volumes
Kewaunee Scientific’s shares have outperformed the Zacks Instruments - Scientific industry over the past six months (+39.2.0% vs. -7.0%). This microcap company with market capitalization of $183.80 million have investment appeal lies in its robust order backlog, which reached a record $184.4 million as of Oct. 31, 2024, growing 26% year over year. This demonstrates strong demand for its lab solutions, bolstered by global R&D investments.
The Nu Aire acquisition expands market leadership, providing new revenue streams and operational synergies. Diversified revenues across life sciences, healthcare and education mitigate sector-specific risks, while a strengthened balance sheet enhances financial flexibility.
However, risks include declining international sales (down 30.1% year over year in the second quarter of fiscal 2025), rising operating expenses (up 13.9% year over year), raw material cost vulnerabilities and project-based revenue reliance. Additionally, limited shareholder returns and foreign currency risks weigh on long-term attractiveness.
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Previewreports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Boston Scientific Corporation (BSX) : Free Stock Analysis Report
ConocoPhillips (COP) : Free Stock Analysis Report
Procter & Gamble Company (The) (PG) : Free Stock Analysis Report
Kewaunee Scientific Corporation (KEQU): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.